Cell No. : Cell Name
RCB1145 : 32D
update : 2024/01/17
|
Comment | IL-3 dependent cells from Friend leukemia virus-infected mouse bone marrow. |
Comment from the depositor | |
Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
Remarks | |
Order Form |
Order Form(C-0005.pdf)
 
MTA(C-0007.pdf)
 
MTA(C-0007p.pdf)
 
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
Basic information
|
Depositor |
Todokoro, Kazuo
|
Year of deposit |
1995
|
Animal |
_mouse
< Mammals
|
Strain name |
C3H/HeJ
|
Tissue |
bone marrow
|
Disease name |
Friend leukemia
|
Classification |
transformed
|
|
Lifespan |
infinite
|
Morphology |
lymphocyte-like
|
Cellosaurus(Expasy) |
CVCL_0118
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Suspension cells
|
Culture method |
|
浮遊細胞の培養に関する一般的な注意(Japanese)
|
Culture medium |
|
RPMI1640 + 10% FBS + 10U/ml rmouse IL-3
|
Antibiotics |
|
Free
|
|
Passage method |
|
dilution
|
Culture information
|
Passage ratio |
|
1 : 10-20 split
|
SC frequency |
|
Subculture : 2 times/week
|
Temperature |
|
37
℃
|
CO2 concentration |
|
5
%
|
Freeze medium |
|
Medium + 10% DMSO
|
Freezing method |
|
Slow freezing
|
Mycoplasma |
|
(-)
|
SSLP(mouse) |
|
OK
|
Isozyme |
|
LD, NP
|
Images |
deposit info | lot info |
|
|
Reference information |
Reference |
6
|
User's Publication |
9
|
Reference |
1980
Reisbach G, Ellwart J, Dormer P
Lactate production and amino acid incorporation in interleukin 3-dependent, factor-deprived hemopoietic murine cell lines.
Exp Cell Res
1990
190:175-8
PubMed ID: 2209720
DOI: 10.1016/0014-4827(90)90182-a
|
5466
Migliaccio G, Migliaccio AR, Kreider BL, Rovera G, Adamson JW.
Selection of lineage-restricted cell lines immortalized at different stages of hematopoietic differentiation from the murine cell line 32D.
J Cell Biol
1989
109(2):833-41
PubMed ID: 2668305
DOI: 10.1083/jcb.109.2.833
|
5467
Pierce JH, Ruggiero M, Fleming TP, Di Fiore PP, Greenberger JS, Varticovski L, Schlessinger J, Rovera G, Aaronson SA.
Signal transduction through the EGF receptor transfected in IL-3-dependent hematopoietic cells.
Science
1988
239(4840):628-31
PubMed ID: 3257584
DOI: 10.1126/science.3257584
|
1983
Le Gros, G S, Shackell, P S, Le Gros, J E, Watson, J D
Interleukin 2 regulates the expression of IL 2 receptors on interleukin 3-dependent bone marrow-derived cell lines.
J Immunol
1987
138:478-83
PubMed ID: 3098845
|
4924
Tweardy DJ1, Caracciolo D, Valtieri M, Rovera G.
Tumor-derived growth factors that support proliferation and differentiation of normal and leukemic hemopoietic cells.
Ann N Y Acad Sci
1987
511:30-8
PubMed ID: 2830826
DOI: 10.1111/j.1749-6632.1987.tb36235.x
|
1979
Greenberger, J S, Sakakeeny, M A, Humphries, R K, Eaves, C J, Eckner, R J
Demonstration of permanent factor-dependent multipotential (erythroid/neutrophil/basophil) hematopoietic progenitor cell lines.
Proc Natl Acad Sci U S A
1983
80:2931-5
PubMed ID: 6574462
DOI: 10.1073/pnas.80.10.2931
|
User's Publication |
21208
Okamoto K, Imamura T, Tanaka S, Urata T, Yoshida H, Shiba N, Iehara T.
The Nup98::Nsd1 fusion gene induces CD123 expression in 32D cells.
Int J Hematol
2023
PubMed ID: 37173550
DOI: 10.1007/s12185-023-03612-z
|
14920
Takita M, Tsukahara F, Mishima T, Ieguchi K, Yamada M, Honda H, Maru Y.
Paradoxical counteraction by imatinib against cell death in myeloid progenitor 32D cells expressing p210BCR-ABL
Oncotarget
2018
9(60):31682-31696
PubMed ID: 30167087
DOI: 10.18632/oncotarget.25849
|
15756
Abe S, Kurata M, Suzuki S, Yamamoto K, Aisaki K, Kanno J, Kitagawa M.
Minichromosome maintenance 2 bound with retroviral Gp70 is localized to cytoplasm and enhances DNA-damage-induced apoptosis
PLoS One
2012
7(6):e40129
PubMed ID: 22768239
DOI: 10.1371/journal.pone.0040129
|
18982
Tsujimura A, Kiyoi H, Shiotsu Y, Ishikawa Y, Mori Y, Ishida H, Toki T, Ito E, Naoe T.
Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia
Int J Hematol
2010
92(4):624-33
PubMed ID: 20890793
DOI: 10.1007/s12185-010-0692-8
|
18683
Kiyoi H, Shiotsu Y, Ozeki K, Yamaji S, Kosugi H, Umehara H, Shimizu M, Arai H, Ishii K, Akinaga S, Naoe T.
A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations
Clin Cancer Res
2007
13(15 Pt 1):4575-82
PubMed ID: 17671144
DOI: 10.1158/1078-0432.CCR-07-0225
|
11005
T Kajiguchi, E J Chung, S Lee, A Stine, H Kiyoi, T Naoe, M J Levis, L Neckers, J B Trepel
FLT3 regulates beta-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells
Leukemia
2007
21(12):2476-84
PubMed ID: 17851558
DOI: 10.1038/sj.leu.2404923
|
4884
Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T.
Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain
Oncogene
2002
21(16):2555-63
PubMed ID: 11971190
DOI: 10.1038/sj.onc.1205332
|
15586
Zhao M, Kiyoi H, Yamamoto Y, Ito M, Towatari M, Omura S, Kitamura T, Ueda R, Saito H, Naoe T.
In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor
Leukemia
2000
14(3):374-8
PubMed ID: 10720129
DOI: 10.1038/sj.leu.2401680
|
4831
Kume A1, Ito K, Ueda Y, Hasegawa M, Urabe M, Mano H, Ozawa K.
A G-CSF receptor-gyrase B fusion gene: A new type of molecular switch for expansion of genetically modified hematopoietic cells.
Biochem Biophys Res Commun
1999
260(1):9-12
PubMed ID: 10381335
DOI: 10.1006/bbrc.1999.0859
|